Ablynx enters into research and license agreement with Wyeth


Ablynx, has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover, develop and commercialise Nanobodies® directed at the tumour necrosis factor alpha (TNF-) protein and its receptors that target diseases in multiple therapeutic areas.

Ablynx has granted Wyeth exclusive worldwide rights to Nanobodies® targeting the clinically validated target TNF-. Ablynx and Wyeth will collaborate to advance these novel biologics through preclinical development. Ablynx will receive an initial payment, research support and milestone payments. Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialisation of multiple products. In addition Ablynx will receive royalties on product sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances